A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With Multiple Myeloma and Kidney Injury

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Multiple myeloma (MM) is still an incurable hematological tumor, and renal involvement is the main factor of poor prognosis. The recovery of renal function can partially reverse its poor outcome. Although the 5-year survival rate of MM patients has significantly improved after entering the era of new drugs, patients with severe renal insufficiency still have a high early mortality.The purpose of this study is to investigate whether early intensive chemotherapy can reverse the proportion of renal insufficiency, is to investigate the treatment effect of RIMM patients with different renal pathological types, and is also to investigate whether autoHSCT can further partially save renal function in RIMM patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Adults aged 18 years or older

• Confirmed diagnosis of symptomatic myeloma with renal impairment

• Confirmed myeloma-associated nephropathy (e.g. light chain cast nephropathy, AL amyloidosis, MIDD etc.) on renal biopsy

• Willingness and eligibility for autologous hematopoietic stem cell transplantation

Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
Bo Tang, PhD.
tangbo8809@163.com
008613521776195
Backup
Yujun Dong, M.D.
dongy@hsc.pku.edu.cn
008618210264969
Time Frame
Start Date: 2024-01-02
Estimated Completion Date: 2025-11-30
Participants
Target number of participants: 30
Treatments
Experimental: BCD-KPD-AutoHSCT
BCD-KPD-AutoHSCT/BCD-AutoHSCT
Related Therapeutic Areas
Sponsors
Leads: Peking University First Hospital

This content was sourced from clinicaltrials.gov